Mast cells are immune cells that release histamine and other inflammatory chemicals during allergic reactions. In Mast Cell Activation Syndrome, these cells release their contents inappropriately — causing flushing, hives, abdominal symptoms, and lightheadedness in response to triggers that should not normally cause them. MCAS is increasingly recognized but requires careful evaluation to distinguish from other conditions.
Mast cells normally play a critical role in immune defense and the inflammatory response. In Mast Cell Activation Syndrome, these cells become hyperactive — releasing histamine, tryptase, leukotrienes, and other mediators in response to triggers that should not normally provoke a reaction. The result is episodes of flushing, hives, abdominal cramping, diarrhea, lightheadedness, and sometimes anaphylactoid reactions.
Diagnosis requires careful evaluation because the symptoms overlap with many other conditions. The current consensus criteria require objective evidence of mast cell mediator release (typically a measured rise in tryptase during an episode), symptoms involving two or more organ systems, and improvement with mast cell-directed therapy. The differential diagnosis includes systemic mastocytosis, hereditary alpha-tryptasemia, carcinoid syndrome, and pheochromocytoma — each of which is approached differently.
Workup includes a baseline serum tryptase level and a tryptase measurement during an episode (typically drawn within one to four hours of onset). A 24-hour urine collection for n-methylhistamine and prostaglandin metabolites adds diagnostic information. When indicated, evaluation for the KIT D816V mutation and screening for hereditary alpha-tryptasemia are performed.
Coordination with hematology may be needed when systemic mastocytosis is on the differential. The evaluation is methodical because labeling someone with MCAS without rigor is unhelpful — and other conditions on the differential have entirely different management.
Treatment focuses on trigger identification and avoidance, layered antihistamine therapy (H1 and H2 blockers), and additional mast cell stabilization with cromolyn or leukotriene modifiers. For patients with persistent symptoms despite optimized standard therapy, omalizumab (Xolair) is sometimes effective.
Patients with anaphylactoid-type reactions are prescribed an epinephrine auto-injector and counseled on its use. A clear written action plan is provided.
A first visit takes a detailed history of episodes — what triggers them, how they manifest, what helps and what does not. Baseline labs are ordered. Patients are counseled on how to obtain tryptase during a future episode if needed for confirmation. Subsequent visits focus on optimizing therapy and ruling out alternative diagnoses if the picture remains uncertain.
Donald L. McNeil, MD · Board Certified in Allergy & Immunology and Internal Medicine
This page is provided for educational purposes and does not substitute for clinical judgment or direct medical advice. Treatment decisions are individualized based on your full history, examination, and laboratory findings. If you have an emergency, call 911.